Dr Natasha Leighl leads the Thoracic Medical Oncology Group at the Princess Margaret Cancer Centre, and holds the OSI Pharmaceuticals Foundation Chair. She is Professor of Medicine at the University of Toronto with over 300 peer-reviewed publications. Her main interest is in developing new treatments in lung cancer and improving access to precision medicine. She has led multiple international and cooperative group studies in lung cancer and serves multiple organizations including ESMO, ASCO, IASLC, The Oncologist, British Journal of Cancer and more.